30 Sep, 2024 EU VAT: Novo Nordisk ruling unlocks VAT refund benefits for pharma companies – key takeaways By Andy van Esdonk On September 12, 2024, the Court of Justice of the European Union (CJEU) delivered a ruling in a case involving Novo Nordisk AS...
19 Sep, 2024 EU Parliament Adopts Position on Pharmaceutical Reform: implications for the Environmental Risk Assessment By Hester Borgers Emma Stok In our earlier article, we discussed the implications of the European Commission’s legislative proposal from 26 April 2023 for the...
17 Sep, 2024 The DNA of Life Sciences Deals By James Baillieu Maria John The life sciences sector, comprising of sub-sectors like pharmaceuticals, medical devices, diagnostics and services, aims to cure disease...
11 Sep, 2024 EU Pharmaceutical Reform: Update on the proposed changes to marketing authorisation procedures By Sally Shorthose Sophie Vo This article is part of our series covering the proposed reforms to the EU pharmaceutical legislation. To view the entire series, click...
05 Sep, 2024 What do the Political Guidelines for the Next European Commission bring to the life sciences & healthcare industry? By Hester Borgers Ana-Maria Barbu-Nyström On 18 July 2024 President Von der Leyen laid down the path for the next European Commission in her Political Guidelines for the next...